Frozen, Old, or New? : Comparing Biochemical Markers and Tissue Oxygenation in Transfused Blood by Wiles, Connor
Portland State University
PDXScholar
University Honors Theses University Honors College
2014
Frozen, Old, or New? Comparing Biochemical Markers and Tissue
Oxygenation in Transfused Blood
Connor Layzan Wiles
Portland State University
Let us know how access to this document benefits you.
Follow this and additional works at: http://pdxscholar.library.pdx.edu/honorstheses
This Thesis is brought to you for free and open access. It has been accepted for inclusion in University Honors Theses by an authorized administrator of
PDXScholar. For more information, please contact pdxscholar@pdx.edu.
Recommended Citation
Wiles, Connor Layzan, "Frozen, Old, or New? Comparing Biochemical Markers and Tissue Oxygenation in Transfused Blood"
(2014). University Honors Theses. Paper 35.
10.15760/honors.34
Frozen, Old, or New? Comparing Biochemical Markers and Tissue Oxygenation in 
Transfused Blood. 
A Baccalaureate Honors Thesis by Connor Wiles  
Honors Department in Conjunction with the Department of Chemistry at Portland 
State University and the Trauma Research Institute of Oregon, Oregon Health and 
Science University 
 
 
Abstract  
 
The transfusion of red blood cells is a necessary therapy used to treat anemia that 
often results from traumatic hemorrhage. The traditional method of storing red blood 
cells prior to transfusion in the United States has been as a liquid in a refrigerated fashion 
at a temperature between two and eight degrees Celsius. Throughout the storage duration, 
the red cells undergo a series of structural, functional, and biochemical changes 
commonly known as the storage lesion. Increased length of storage has been associated 
with increased rates of infection, as well as higher incidents of mortality. We 
hypothesized that this prospective, randomized, double blinded study would demonstrate 
that a cryogenic freezing method of storing blood would result in higher tissue 
oxygenation for the patient, an increased biochemical profile of the blood, and decreased 
rates of negative outcomes compared to the liquid preservation method. 
Adult trauma patients with an injury severity score of greater than 4 and an 
anticipated need for transfusion of at least one unit of blood were randomized to receive 
either CPRBCs or LPRBCs. 57 patients were randomized and received blood transfusions 
as part of either of the two groups. 22 patients received CPRBCs, and 35 patients 
received LPRBCs. Tissue oxygenation as well as 2,3-DPG concentration, (p<0.05) was 
elevated in the patients whom received CPRBCs over the patients that received LPRBCs. 
The serum concentrations of haptoglobin, serum amyloid p, and C-reactive protein were 
all decreased in CPRBC units compared to the LPRBC units. Pro-inflammatory cytokines 
IL-8 and TNF-α were elevated in the LPRBC group compared to the CPRBC group 
(p<0.05). Finally the D-dimer, which is an indicator of fibrinolysis, was higher in the 
LPRBC group (p<0.05).  
In conclusion, CPRBCs maintain a superior biochemical profile over LPRBCs, as 
well as provide potential for higher tissue oxygenation in patients, and also present a 
viable option to combat the severe blood shortage that constantly exists in the United 
States, by extending the shelf life of RBC units to ten years. This extension of storage 
time may also result in the prevention of an $80 million loss annually. 
 
Introduction 
 
Anemia is defined as a decrease in the amount of red blood cells, or a less than 
normal concentration of hemoglobin in the blood. In trauma patients, this condition is 
usually onset by hemorrhage and the resulting coagulopathy from the injuries. Due to the 
methods of resuscitation, the often-urgent need for surgical intervention, the requirement 
for serial blood draws, and the abnormality of red blood cell (RBC) production in these 
patients, they are not often able to keep up with the body’s requirement for oxygen. In 
order to combat this issue, critically ill patients in the intensive care units receive an 
average of five units of packed red blood cells (PRBC). 1 Patients often receive 
transfusions of PRBC’s in order to restore and maintain intravascular blood volume as 
well as increase blood pressure. Patients may also receive transfusions in order to 
increase oxygen perfusion in systemic tissues and organs, with the ultimate goal of 
preventing organ failure and death. 2-4  
The efficacy of the PRBC units is dependent on the RBC to traverse a network of 
micro-capillary blood vessels, reach the tissues, and offload the oxygen molecules it is 
carrying5,6. Unfortunately, while awaiting transfusion, these units go through a series of 
structural and biochemical changes and develop a well documented storage lesion.7 These 
changes adversely affect the cells life span, as well as its shape and plasticity, which in 
turn negatively affect the cells ability to navigate the capillary networks and deliver 
oxygen to the tissues that need it. Changes in the nitric oxide (NO) metabolism, increases 
in the concentration of free hemoglobin, decreases in the concentration of 2,3-
diphosphoglycerate (2-3 DPG), increased hemolysis, and residual leukocytes as well as 
platelets are additional factors that contribute to the storage lesion. NO depletion is an 
especially concerning issue as it is a crucial contributor to vasodilation witch enables 
blood to reach end tissue easier, and can decrease blood pressure. 
Likely as a result of this storage lesion, the transfusion of liquid preserved red 
blood cells (LPRBCs) has been linked to a longer hospital length of stay, prolonged 
coagulation times, an increase in the number of infections, increased occurrence of 
trauma related acute lung injury (TRALI), multiple organ dysfunction syndrome, and 
death8,9-15. Longer storage times for LPRBC’s have been associated with increases in 
these as well as other complications16. By nature of the donation process, donated blood 
is a mix of RBCs at varying time points along their life cycle. At this point it is 
impractical for banked blood to be selected for based on the cells age. However, the 
method used to store the blood can either have a neutral or negative effect, which will 
ideally leave them arrested in the state in which they were donated or further degrade the 
donated cells. 
Currently, the Food and Drug Administration (FDA) approve LPRBCs, for 
storage at a temperature between two and eight degrees Celsius for up to 42 days. The 
RBCs are separated from the plasma and leukocytes, a solution of citrate-phosphate-
dextrose-adenine is added, and the units are brought down to the desired temperature. 
Although erythrocyte metabolism is decreased at these temperatures, cells still undergo 
the morphologic changes that were described above.7 After observing these changes in 
conjunction with the many complications and negative outcomes associated with blood 
transfusions thought to be associated with storage methods, a method of freezing blood 
for prolonged safer storage was identified. 
In 1950, Smith17 discovered that a small amount of blood mixed with glycerol 
could be cooled to a temperature of -70 degrees Celsius. Not long after, this method was 
further investigated and developed in order to freeze entire units of PRBCs while 
retaining normal function18. Many cell-specific cryopreservation protocols have been 
developed since that time. The methods vary in their processing techniques, as well as red 
cell concentrations, types of protective solutions, rates of thawing and freezing, storage 
temperature, and glycerol concentration. In the United states we use a high glycerol 
concentration in conjunction with a slow freezing and cooling process19. The process of 
thawing and washing the cells in order to remove the glycerol from the units must be 
carefully controlled in order to prevent the lysis and degradation of the cells. In order to 
prevent the storage lesion from developing before the freezing process, the American 
Association of Blood Banks require RBCs to be frozen within 6 days of collection20. The 
FDA approved a storage period of up to ten years for glycerol frozen RBCs at a 
temperature of -80 degrees Celsius. 
In addition to the physiologic implications of transfusing LPRBCs, there is also 
the issue of blood shortages that are not able to be adequately addressed using this 
method, as well as the huge financial loss that our as well as other countries, suffer as a 
result of relying solely on this method. Due to the 42-day shelf life of LPRBCs, the units 
that reach this time point must be discarded, and has amounted to a loss of approximately 
$80 million annually. Based on the shelf life, there are also seasonal and cyclical 
shortages that effect patient management. America’s blood center’s STOPLIGHT, which 
is the blood monitoring program in the United States, has reported that 30% of national 
sites had only a two day supply of blood on hand at any given time21. Although blood 
donation always increases during times of national disasters, it often takes up to two days 
for the blood to reach the locations and people that need it. Many lives are lost 
unnecessarily due to this issue that could be easily solved with a supplemental blood-
banking program. Enter cryopreservation of banked blood. 
During the conflict in South East Asia in the 1960s the FDA had approved storage 
for LPRBCs to a shortened 21-day period. This truncation of the storage period resulted 
in the destruction of almost 50% of the banked blood that Americans had overseas. 
Fortunately a significant number of Cryopreserved red blood cell (CPRBC) units had 
been sent to Da Nang, Vietnam around the same time. The CPRBCs virtually eliminated 
the deficit, and in addition, the patients whom had received the units experienced little or 
no transfusion reactions compared to the group that had received the LPRBCs22. 
Following the conflict in Vietnam, a number of institutions in the United States 
developed and implemented a cryopreserved blood storage program. Among them were 
Massachusetts General Hospital, Cook County Hospital, and 30 other institutions23. The 
institutions that developed CPRBC storage programs used them as a supplement to their 
LPRBC programs, and they were very successful. However, due to the FDA eventually 
approving a 42-day shelf life for the LPRBCs, as well as advancements in the liquid 
storage techniques, the CPRBC programs were virtually abandoned. Although there are 
still CPRBC programs in the United States, we see them only in military settings such as 
the conflict in the Middle East, as well as small programs that help preserve units of rare 
blood types. 
Historically the process of cryogenically freezing blood units has been timely, 
costly, and not as safe as LPRBC storage. The process was performed in an open system 
that was labor intensive and required technicians to manually inject the units with the 
glycerol substrate, and then wash them through various filters after they were thawed. 
This process was not only time consuming, but also introduced unnecessary risk for 
contamination. Furthermore, the units were only approved for a 24 hour storage period 
after the units had been thawed24. The Haemonetics Corporation (Braintree, MA) has 
developed an automated system that has virtually removed all possibility for 
contamination and greatly increased the efficiency of the entire process. This has become 
the standard of practice for our institution’s CPRBC program. Currently, we are using the 
Automated Cell Processor (ACP) 215, which simultaneously thaws and deglycerolizes 
the blood units in a closed system. The machine is easy to use, and can simultaneously 
process two units at a time. When this machine is used for the deglycerolization process, 
the FDA has approved a 14-day shelf life at 4 degrees Celsius in standard storage 
solutions for each unit post thaw25.  
Recently, evidence from multiple studies has shown that the duration of storage 
for blood products greatly affects the efficacy and safety to the patient. In an ideal world, 
a fresh product that was transferred directly from donor to recipient would be supplied 
when the need for transfusion arises. Sadly, this will likely never be possible, and to 
shorten the allowed length of time for storage, would greatly and negatively affect our 
nation’s blood supply. With the addition of a cryopreserved blood program used as a 
supplement to the already robust liquid storage program, we may be able to greatly 
increase the outcomes of our patients as well as save money for our institutions. Although 
a frozen blood storage program has been utilized in the military and academic setting, a 
widespread application in the civilian setting has yet to be explored26-28. Based on the 
body of evidence that supports negative results due to the storage lesion that develops 
after long term refrigerated storage, and the possible benefits of a frozen blood storage 
program, we have performed a pilot study to assess the theoretical advantages of this 
program with regard to tissue oxygenation and biochemical changes compared to the 
liquid preservation technique. Clinical outcomes, tissue oxygenation, and biochemical 
changes were assessed recognizing that the study was not adequately powered to make 
strong conclusions, but may provide evidence as to whether or not cryopreservation 
might be a valid supplemental method for the storage of blood products. 
 
 
RESEARCH DESIGN AND METHODS 
 
This was a prospective, randomized, double-blinded study. Approval from the 
university’s Institutional Review Board was obtained. Patients were considered eligible if 
admitted to the Oregon Health and Science University trauma service with an Injury 
Severity Score (ISS) of greater than 4 and an anticipated need for a blood transfusion. 
Exclusion criteria included inability to obtain consent, massive transfusion within the 
previous three months, blood transfusion within the previous 24 hours, requirement for 
emergent transfusion, bilateral hand injuries, patients whom were pregnant, and children 
that were less than 15 years old. Patients requiring emergent transfusions were excluded 
on the basis of the frozen blood’s requirement of a two-hour time period during which the 
units were thawed and deglycerolized. Patients with bilateral hand injuries were excluded 
on the basis of our requirement for placing the tissue oxygenation (StO2) monitor on the 
patient’s thenar eminence. Consent was obtained from the patient or legally authorized 
representative prior to transfusion of the first unit of blood.  
Patients were initially randomized to one of three groups, new blood, old blood, 
or cryogenically frozen blood. Patients randomized to the new blood group would receive 
a transfusion of LPRBCs that had been stored for a period of no longer than 14 days. 
Patients randomized to the old blood group would receive LPRBCs that were stored for a 
period of time between 14 and 42 days. Patients randomized to the frozen blood group 
would receive CPRBCs that had been stored cryogenically for varying amounts of time. 
Due to the lack of a statistically significant difference between the two LPRBC groups, 
they were combined to create one group of patients that received blood between the ages 
of 1 and 42 days old, stored in the traditional refrigerated fashion. 
Once patients were randomized to one of the groups, the blood bank was 
immediately notified of their enrollment in the study. Blood bank staff would randomize 
the patients to one of the three groups using a random numbers generating program which 
related the number selected, to a number on a list corresponding to a specific group. 
Upon request by the treatment team for blood products for an enrolled patient, the blood 
bank would begin the thawing and deglycerolizing process if the patient were randomized 
to the frozen blood group. If the patient had been randomized to one of the other two 
groups, they would simply hold the refrigerated products for a time period of two hours. 
This was to maintain the blindness for the research staff, as well as the treatment team.  
Following notification of the blood bank of a patient’s enrollment, the research 
staff would collect basic demographic information on the enrolled subject. The 
information collected included sex, age, race, and ISS. Information such as outcomes, 
complications, and hospital length of stay, organ failure, transfusion reactions, surgeries, 
thrombotic events as well as mortality were also collected. A patient’s participation in the 
study in no way affected their chances of receiving a transfusion, and all decisions to 
transfuse a patient were made at the discretion of the primary treatment team. In our 
facility patients will likely receive a transfusion if their hemoglobin level is less than 7 
g/dL for normal patients, and less than 8 g/dL if the patient had incurred a head injury. 
Multiple methods of cross matching were used based on the results of the 
patient’s initial antibody screen. A serologic test, Antiglobulin, was performed using the 
Gel microtube method if a patients serum showed no sign of antibodies. In this case, if 
there were also no discrepancies found in the ABO, and RH positive or negative type, 
then an electronic cross match was performed. If no antibodies were present in the serum, 
and discrepancies in the ABO, RH type was however found, then an immediate spin 
serologic test was performed. 
Once the primary treatment team had placed an order for blood products for an 
enrolled patient, the research coordinator on call would receive a page notifying them of 
the order. The coordinator would then retrieve a near-infrared spectroscopy device 
(Hutchinson Technology, Hutchinson, MN) and place it on the patient’s thenar eminence 
prior to transfusion of the products, and this would remain there for twelve hours post 
transfusion. The instrument works non-invasively by penetrating the tissue with near-
infrared light that is able to measure the concentration of hemoglobin loaded with oxygen 
as well as the hemoglobin that is not carrying oxygen. The instrument calculates a ratio of 
oxygenated to deoxygenated hemoglobin and returns the value as a percentage of tissue 
oxygen saturation.29  
After placing the StO2 Monitor, the research staff would then collect a 10cc 
baseline blood sample before the transfusion began. Blood samples were also collected 
from the patient post transfusion of the first unit, and following the transfusion of a 
second unit if one were administered. A 12-hour post transfusion time point blood sample 
was also obtained for all subjects. For each of these time points a thromboelastogram 
(TEG), as well as a complete blood count (CBC) was ordered. Standard coagulation tests 
as well as a D-dimer (Diagnostica Stago Inc., Parsippany, NJ), was also performed on the 
human samples. After the blood had been hung, 300cc of the unit was allowed to 
transfuse into the patient, and at that point a 12cc blood sample was taken from the blood 
unit itself. A sample of the same volume was taken from each additional unit that the 
patient received. All human samples as well as samples taken from the individual units 
were assayed for biochemical markers and changes. The Bio-Plex Pro Human Acute 
Phase 4-Plex Panel (Bio-Rad Laboratories Inc., Hercules, CA) was used to assess 
Haptoglobin (Hg), serum amyloid P (SAP) and C-reactive proteins (CRP). Hg was used 
as an indicator that assessed the degree of hemolysis of the red blood cells in each 
sample, as it is a free hemoglobin scavenger. SAP and CRP were assessed because of 
their known anti-coagulation effects. Combined with Heparin, SAP can cause a 
hypocoagulable state30,31. A sievers Nitric Oxide analyzer 280i (GE Analytical 
Instruments, Boulder, CO) was used to measure NO metabolites. A commercially 
available kit (Roche Diagnostics, Indianspolis, IN) was used to analyze the levels of 2,3-
DPG in each sample. The Human Cytokine 8-Plex Assay (Bio-Rad Laboratories Inc., 
Hercules, CA) was used to measure cytokines IL-2, IL-4, IL-6, IL-8, IL-10, GMCSF, 
TNF-α, and IFN-γ. 
If a patient suffered from organ failure, the data was assessed in order to look for 
correlations between the complication and the transfusion. Adult respiratory distress 
syndrome (ARDS) was defined using the American-European consensus conference32. 
The Denver Multiorgan Failure score was used to grade multiple organ failure33. RIFLE 
classification as outlined by the Acute Dialysis Qualitative Initiative Workgroup was 
used to asses acute renal failure34. Mean differences in maximum and minimum StO2 data 
compared to baseline values were used to determine changes in oxygenation. An area 
under the curve analysis was used in order to identify trends as well as correct for minute-
to-minute fluctuations in oxygenation that is typical of StO2 measurements. 
Measurements taken at baseline, during transfusion, as well as post transfusion of the 
blood products were compared within each group and between each group. The data was 
found to be normally distributed, and was evaluated using student t-tests. 
SPSS version 19 (IBM, Armonk, NY) was used to analyze all data. Continuous, 
normally distributed data were analyzed using Analysis of Variance (ANOVA) and 
paired student t-tests. Non-parametric data were analyzed using a Mann-Whitney U and 
Wilcoxon Rank Sum tests. Significance was set at the 95% confidence interval with a p 
value of less than 0.05. 
  
RESULTS 
 
A total of 57 patients participated in this study. Thirty-five patients received 
LPRBCs while the remaining twenty-two received CPRBCs. 11 patients whom received 
LPRBCs received two consecutive units, while 9 patients whom received CPRBCs were 
transfused two units (p=0.57). Median time for transfusions was 135 minutes (75-209 
minutes). Both groups were similar in age, sex, mechanism of injury, ISS, and APACHE 
II score (Table 1). The length of storage for the CPRBCs was significantly longer with a 
mean age of 588 days while the LPRBCs mean storage age was 14 days (Table 2).  
 
 
 
 
 
 
 
(n total=57) 
LPRBC 
Group 
(n=35) 
CPRBC 
Group 
(n=22) 
p value 
Age, median (IQR) 44 (30-54) 50 (26-66) 0.56 
Gender (Male/Female) 23/12 16/6 0.58 
Mechanism of Injury 
(blunt/penetrating) 34/1 19/3 0.29 
ISS, median (IQR) 26 (13-33) 18 (10-27) 0.18 
APACHE II Score, 
mean (SD) 11 (5) 11 (5) 0.88 
Table 1 Patient demographics. 
(n	  total=57)	  
LPRBC	  
Group	  
(n=35)	  
CPRBC	  Group	  
(n=22)	  
Storage	  duration	  
(days),	  median	  (IQR)	  	  
14	  (9.8,	  27.3)	  	   588	  (392,	  756)	  	  
Haptoglobin	  (ng/mL),	  
median	  (IQR)	   73	  (31,	  105)	  	   10	  (4,	  32)	  	  
C-­‐reactive	  Protein	  
(ng/mL),	  median	  
(IQR)	  
5	  (2,	  10)	  	   0.1	  (0.0,	  1.7)	  	  
Serum	  amyloid	  p	  
(ng/mL),	  median	  (IQR)	   34	  (22,	  54)	  	   1.8	  (0.6,	  13.5)	  	  
Table	  2	  Stored	  blood	  characteristics	  for	  LPRBCs	  and	  CPRBCs	  (p<0.01)	  
The CPRBCs were found to have decreased serum concentrations of Hg, SAP, 
and CRP compared to the LPRBCs (Table 2). Pro-inflammatory cytokines IL-8 and TNF- 
α were elevated compared to baseline values in the LPRBC group, and this elevation was 
not observed in the CPRBC group (Figures 1,2). There was no difference observed in 
pro-inflammatory cytokines IL-2, IL-6, INF- γ, or GMCSF in either of the two groups at 
any time point (Figures 3-6). Nor was there a difference observed in anti-inflammatory 
cytokines IL-4, or IL-10 in either group at any of the time points (Figures 7,8). No 
difference in NO metabolites was observed in either group (Figure 9). The D-dimer was 
elevated in the LPRBC group at the 12 hour post transfusion time point (Figure 10) A 
difference in the concentration of 2,3-DPG between the two groups became statistically 
significant following transfusion of the second unit of blood and persisted through the 12 
hour time point  (Figure 11). 
 
	  
Figure	  1	  IL-­‐8	  concentration	  at	  baseline	  and	  12-­‐Hr	  time	  point	  for	  LPRBCs	  and	  CPRBCS	  
	  
Figure	  2	  TNF-­‐α	  concentration	  at	  baseline	  and	  12-­‐Hr	  time	  point	  for	  LPRBCs	  and	  CPRBCS	  
	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  3	  IL-­‐2	  concentration	  at	  baseline	  and	  12-­‐Hr	  time	  point	  for	  LPRBCs	  and	  CPRBCS	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Figure	  4	  IL-­‐6	  concentration	  at	  baseline	  and	  12-­‐Hr	  time	  point	  for	  LPRBCs	  and	  CPRBCS	  
	  
Figure	  5	  INF-­‐γ	  concentration	  at	  baseline	  and	  12-­‐Hr	  time	  point	  for	  LPRBCs	  and	  CPRBCS	  
	  
Figure	  6	  GMCSF	  concentration	  at	  baseline	  and	  12-­‐Hr	  time	  point	  for	  LPRBCs	  and	  CPRBCS	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Figure	  7	  IL-­‐4	  concentration	  at	  baseline	  and	  12-­‐Hr	  time	  point	  for	  LPRBCs	  and	  CPRBCS	  
	  
	  
Figure	  8	  IL-­‐10	  concentration	  at	  baseline	  and	  12-­‐Hr	  time	  point	  for	  LPRBCs	  and	  CPRBCS	  
	  
Figure	  9	  Concentration	  of	  NO	  Metabolites	  from	  baseline	  through	  12-­‐Hr	  time	  point	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Figure	  10	  D-­‐Dimer	  concentration	  at	  baseline	  and	  12-­‐Hr	  time	  points	  (p<0.05)	  
	  
Figure	  11	  Concentration	  of	  2,3-­‐DPG	  at	  each	  time	  point	  in	  the	  LPRBC	  and	  CPRBC	  groups	  (p<0.05)	  
The mean values for StO2 data throughout the study were compared between the 
two groups of patients. Only data that was continuously collected for patients through the 
twelve-hour time point was considered valid. After removing patients that had 
discontinuous data, there were 20 patients in the CPRBC group that were compared with 
30 Patients in the LPRBC group. At baseline, there was no statistically significant 
difference in the tissue oxygenation between the two groups. However, from the time of 
transfusion initiation up through three hours post transfusion, the patients whom received 
CPRBCs demonstrated an increase in tissue oxygenation over the patients whom received 
LPRBCs. An elevated StO2 tracing was noticed in the CPRBC group following the 180 
minute time point, but was no longer statistically significant after that time. 
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Figure	  12	  StO2	  tracing	  from	  baseline	  through	  the	  12-­‐Hr	  time	  point	  for	  LPRBC	  and	  CPRBC	  groups 
While this study was not powered to demonstrate statistically significant 
differences in clinical outcomes, additional data were also assessed to screen for any 
major safety differences. No gross differences were noted between the two groups when 
comparing rates of respiratory failure, acute renal failure, organ failure, post transfusion 
fever, transfusion reactions, deep venous thrombosis, mortality, or median hospital length 
of stay (Table 3). There were no differences observed in TEG parameters (Table 4), with 
the exception of a slightly greater α-angle in the cryopreserved group following 
transfusion of the second RBC unit. Hematocrit (HCT) was evaluated before transfusion, 
immediately after transfusion, 12 hours after transfusion, and just before discharge. No 
differences were noted in HCT change following transfusion between the groups, and this 
remained true through the point of discharge (Fig. 13).  
 
(n total=57) 
LPRBC 
Group 
(n=35) 
CPRBC Group 
(n=22) p	  value	  
Respiratory 
Failure 32% 32% 0.97 
Acute Renal failure 9% 5% 0.54 
multiple-organ 
failure 12% 9% 0.75 
Post transfusion 
fever 3% 0% 0.42 
Transfusion 
reaction 0% 0% NA 
Deep venous 
thrombosis 15% 32% 0.13 
Mortality 0% 0% NA 
Hospital length of 
stay, median (IQR) 11 (7-16) 16 (9-27) 0.1 
Table	  3	  Outcomes	  for	  patients	  randomized	  to	  either	  of	  the	  two	  groups. 
  LPRBC Group CPRBC Group p value 
Baseline (R)  6.0 ± 1.7 5.9 ± 1.8  0.85 
Post transfusion 
unit 1 (R)  6.6 ± 1.6  6.0 ± 1.2  0.32 
Post transfusion 
unit 2 (R)  6.4 ± 1.4 5.9 ± 2.1  0.5 
12-h post 
transfusion (R)  6.3 ± 1.9  6.9 ± 2.4  0.44 
Baseline (MA)  70.1 ± 8.6  73.1 ± 8.2  0.27 
Post transfusion 
unit 1 (MA)  70.8 ± 7.0  69.8 ± 8.9  0.71 
Post transfusion 
unit 2 (MA)  66.4 ± 7.6  70.5 ± 7.3  0.19 
12-h post 
transfusion (MA)  71.3 ± 7.9  72.8 ± 7.4  0.57 
Baseline (α angle)  70.6 (67.3-73.2)  73.1 (67.7-75.9)  0.19 
Post transfusion 
unit 1 (α angle)  
68.1 (64.3-
72.2)  70.7 (65.5-75.4)  0.24 
Post transfusion 
unit 2 (α angle)  
66.7 (62.0-
69.2)  71.7 (68.3-75.6) 0.01 
12 hours post 
transfusion (α 
angle)  
68.3 (63.5-
72.7)  68.3 (63.8-74.9)  0.89 
Table	  4	  TEG	  Values	  for	  LPRBC	  and	  CPRBC	  groups;	  median,	  (IQR).	  R	  is	  the	  time	  to	  clot	  formation,	  MA	  is	  
maximum	  clot	  strength,	  and	  α	  -­‐angle	  is	  the	  fibrin	  cross-­‐linking.	  
	  
Figure	  13	  Hematocrit	  levels	  for	  LPRBC	  and	  CPRBC	  groups	  at	  baseline	  and	  at	  the	  time	  of	  discharge	  
 
DISCUSSION 
  
The goals of any blood transfusion are to restore intravascular volume to an ideal 
range, increase and maintain blood pressure, increase peripheral tissue oxygenation, and 
ultimately to prevent organ failure and death. Blood storage techniques have developed 
as an ongoing process that has come a long way from where they originated. Today the 
LPRBC storage techniques are very safe from contamination, and have removed almost 
all risk of disease transmittance from donor to recipient. However the ideal 
concentrations and types of preservative solutions, storage length, and temperatures have 
yet to be determined in order to optimize the benefit to the patient. 
 Due to the increasingly large body of research that supports the existence of a 
storage lesion, and the fact that the storage lesion’s detrimental effects are exacerbated as 
the length of storage time increases, storage methods have been identified as a potential 
target for improvement. The lesion has been linked to hypoxia35, increased mortality, 
longer hospital lengths of stay, organ failure52, inflammatory protein related 
hypocoagulation30,31,36 hyperkalemia associated cardiac arrythmias8, and increased levels 
of free hemoglobin which has been linked to patients becoming hypertensive and 
developing acute renal tubular injuries 8,37,38 as well as many others, but the risks of 
transfusions still do not outweigh the benefits to the patient in most cases. Our 
responsibility to patients is to maximize the benefit while decreasing the risks as much as 
possible. 
 Although not adequately powered to make these conclusions, this study has 
shown no significant differences in clinical outcomes between the groups whom received 
CPRBCs and LPRBCs. These conclusions will be more closely examined at, and 
assessed for clinical significance with the multi-center study that is currently underway, 
but they have provided insight about the gross trends we are looking for. The main 
differences that our study identified, and was powered to look at were found in the 
difference in tissue oxygenation between the two blood groups as well as the difference 
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in the concentration of 2,3-DPG and the elevated levels of pro-inflammatory cytokines 
that were observed in the LPRBC group. The CPRBC group showed an elevated level of 
tissue oxygenation from the time of transfusion initiation through the three-hour time 
point, and was statistically significant throughout this period of time. The trend continued 
through the twelve-hour time point, but was no longer statistically significant ager 180 
minutes. It is likely that the increased tissue oxygenation results from the superior 
biochemical profile that is associated with the CPRBC units. 
 Our institution published a study that demonstrated that LPRBCs stored for a 
period of 20 days or less had no effect on the tissue oxygenation of patients, and LPRBCs 
that had been stored for a period of time greater than 21 days decreased the patient’s 
tissue oxygenation35. Based on our data, and seeing these trends now in multiple studies, 
it is theorized that the decrease in oxygenation may be linked to a lacking biochemical 
profile that usually aids in the offloading of oxygen. 2,3-DPG, which promotes the 
offloading of the oxygen molecules has been shown here to be decreased with the liquid 
storage method, and this decrease can be due to the acidic environment created by the red 
cells metabolizing glucose and generating protons during liquid storage that can degrade 
the molecule8,20. Data has shown that cryopreservation at these temperatures arrests the 
biochemical pathways that are associated with this increased acidity, and seems to 
explain the superior biochemical profile associated with the CPRBC group. 
 O’Brien and Watkins39 has shown that after thawing the CPRBC units, the levels 
of 2,3-DPG found in the individual units were similar to the levels found when they were 
frozen, and that their concentration was only affected by the amount of time between 
donation and freezing. 
 As the storage time increases and the storage lesion evolves, a major consequence 
is the devolution of the RBCs from deformable biconcave discs to non-deformable 
spheroechinocytes7. This structural change in the red cells promotes adherence to the 
vascular endothelium, and prevents them from being able to navigate the small capillary 
networks in peripheral tissue, which further prevents oxygen from reaching the hypoxic 
tissues that need them40.  
 During the thawing and deglycerolizing process that occurs before CPRBCs are 
transfused, they undergo a washing process as well. This may have an additional 
beneficial effect on the units by removing unwanted lysed cells, free hemoglobin, and 
other harmful proteins. A study is currently being designed that will look at the washing 
process independent of the CPRBC units. 
 Up to 30% of RBCs in blood units that are greater than 42 days old are considered 
non-viable, and when transfused, the body immediately removes them from circulation.  
Not only do the cells become non-viable, but they also dump their contents into the blood 
stream as they lyse. This increases the concentration of free hemoglobin, which is a 
known NO scavenger41. NO is a potent and crucial vasodilator that is a necessary 
component in order to widen vessels and allow the blood cells to gain access to the 
tissues that need them. 
 StO2 changes are commonly used as predictors of mortality in trauma as well as 
neurological patients29. The near infrared monitoring method we used to obtain the StO2 
data for these patients has been widely used to asses tissue perfusion in applications such 
as cerebral monitoring and monitoring for compartment syndrome42,43. The fact that 
tissue oxygenation which is crucial to patients survival and rapid healing is decreasing 
based on the length and method of storage, is an indicator that something must be 
changed in order to preserve the potential of PRBCs. 
 With the decreased oxygenation, the inferior biochemical profile, the inability to 
mobilize blood units for seasonal demands and natural disasters, and the more than $80 
million loss annually that results from our nation maintaining only a liquid preservation 
method of storage for PRBCs, it is clear there are advantages to having a supplemental 
cryogenic blood storage program. This study has begun to demonstrate that the Method 
of cryogenically freezing red blood cells is safe, maintains a superior biochemical profile, 
achieves increased levels of tissue oxygenation over liquid storage and provides the 
possibility of huge cost savings and better patient care. Currently we are in the middle of 
a multi-center study using similar methods that is better powered to make the conclusions 
we have outlined, and will look closer at the outcomes and transfusion reactions 
associated with patients receiving red blood cells. 
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